Research priorities in bronchiectasis

Thorax

Volumn 68, Issue 7, 2013, Pages 695-696

  De Soyza, Anthony ^a   Brown, Jeremy Stuart ^b   Loebinger, Michael R ^c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Host Defence Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; MACROLIDE;

ARTICLE; BRONCHIECTASIS; CONTROLLED CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DISEASE ASSOCIATION; ENTERITIS; EVIDENCE BASED MEDICINE; GENETIC SUSCEPTIBILITY; HEALTH CARE UTILIZATION; HUMAN; LUNG CLEARANCE; LUNG INFECTION; MEDICAL RESEARCH; MORTALITY; MUCOSAL IMMUNITY; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RESEARCH PRIORITY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; UNITED KINGDOM; UNITED STATES;

BRONCHIECTASIS;

BIOMEDICAL RESEARCH; BRONCHIECTASIS; GREAT BRITAIN; HUMANS; PULMONARY MEDICINE; SOCIETIES, MEDICAL;

EID: 84879417221     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202893     Document Type: Article

References (5)

1. Pasteur MC, Bilton D, Hill AT. British thoracic society non-CF bronchiectasis guideline group. British thoracic society guideline for non-CF bronchiectasis. Thorax 2010;65:577.
2. Weycker D, Edelsberg JE, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005;12:205-9. (Pubitemid 41098340)
3. Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000-2007. Chest 2012;142:432-9.
4. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380:660-7.
5. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009;34:843-9.